308 related articles for article (PubMed ID: 23777769)
41. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
Nabhan C; Zhou X; Day BM; Dawson K; Zelenetz AD; Friedberg JW; Cerhan JR; Link BK; Flowers CR
Am J Hematol; 2016 Aug; 91(8):770-5. PubMed ID: 27124800
[TBL] [Abstract][Full Text] [Related]
42. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
43. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
45. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
46. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
47. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
48. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
49. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
[TBL] [Abstract][Full Text] [Related]
50. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Kahl B
Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
[TBL] [Abstract][Full Text] [Related]
51. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
52. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
53. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
54. The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras.
Nabhan C; Aschebrook-Kilfoy B; Chiu BC; Kruczek K; Smith SM; Evens AM
Am J Hematol; 2014 Jun; 89(6):633-8. PubMed ID: 24633911
[TBL] [Abstract][Full Text] [Related]
55. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
56. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.
Jones B
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 23999211
[No Abstract] [Full Text] [Related]
57. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
[TBL] [Abstract][Full Text] [Related]
58. Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.
Wrench D; Montoto S
Nat Rev Clin Oncol; 2010 Dec; 7(12):677-8. PubMed ID: 21116237
[No Abstract] [Full Text] [Related]
59. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
[TBL] [Abstract][Full Text] [Related]
60. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]